OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
ABC-AF Bleeding ScoreABC-AF Stroke ScoreABCD2 ScoreADD-RSAortic Valve Calcium ScoreAPPLE ScoreASCVD (Pooled Cohort)AVA (Continuity Equation)BAG-AHF ScoreBiplane Simpson EFBlood Pressure PercentilesBrugada Criteria (VT vs SVT)Cardiac Output IndexCHA2DS2-VAScCHADS2Cornell Voltage CriteriaCRUSADE Bleeding ScoreDAPT ScoreDASIDuke Treadmill ScoreE/A RatioEDACS ScoreEHMRGEHRA ScoreEmbolic Risk ScoreEROA (PISA Method)EuroSCORE IIFFR (Fractional Flow Reserve)Fick Cardiac OutputFramingham 10-Year RiskFriedewald LDL EquationGorlin EquationGRACE ScoreGupta MICA (NSQIP)GWTG-HF ScoreH2FPEF ScoreHakki FormulaHAS-BLEDHEART PathwayHEART ScoreHEMORR2HAGEShs-Troponin 0h/1h ESC AlgorithmiFRINTERCHEST ScoreKillip ClassificationLee's RCRILV Mass IndexLV Stroke Work IndexMAGGIC Risk ScoreMAP CalculatorMartin/Hopkins LDLModified Duke CriteriaModified Sgarbossa CriteriaMVA (Pressure Half-Time)Non-HDL CholesterolNT-proBNP Age-Adjusted ThresholdsORBIT ScoreOttawa Heart Failure RiskPulse PressurePVR CalculatorPVR IndexQRISK3QTc (Bazett)QTc (Fridericia)REVEAL 2.0 ScoreReynolds Risk ScoreROSIRVSP CalculatorSchwartz Score (LQTS)SCORE2Seattle Heart Failure Model (SHFM)Sgarbossa CriteriaShock IndexSokolow-Lyon VoltageStroke Volume IndexSVR CalculatorSYNTAX ScoreSYNTAX Score IITAPSETeichholz FormulaTIMI (STEMI)TIMI (UA/NSTEMI)Troponin Delta CalculatorValvular GradientsVancouver Chest Pain RuleVereckei AlgorithmWATCHDM ScoreWilkins ScoreWood Units Calculator

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • First-line RV systolic function assessment on echocardiography
  • Screening for RV dysfunction in pulmonary hypertension
  • Risk stratification post-MI (especially inferior/RV infarction)
  • Serial monitoring in HF, PH, and after lung transplant
  • Prognostic indicator in acute decompensated HF

Key Advantages

  • Simple M-mode measurement; reproducible and operator-independent
  • No contrast required; works in poor acoustic windows
  • Correlates with RV EF from cardiac MRI
  • ESC/ASE endorsed; part of routine echo protocols
CLINICAL INSIGHT

How it Works

Measurement Technique

  • Obtained in apical 4-chamber view (M-mode)
  • Cursor placed at lateral tricuspid annulus (not at RV free wall)
  • Measure systolic displacement from annular position in diastole to systole
  • Measured in mm; independent of image angle

Normal & Abnormal Values

TAPSE (mm)RV Systolic FunctionPrognosis
>16NormalNormal RV function
14–16Mild DysfunctionMildly reduced
11–14Moderate DysfunctionModerately reduced
<11Severe DysfunctionSevere reduction; high mortality risk
CLINICAL INSIGHT

Practical Pearls

Technical Notes

  • Must be lateral annulus (not at septum); septum shows reduced excursion by design
  • Reported as single value; not averaged across cardiac cycles
  • Angle-independent; true linear excursion measurement
  • Reduced TAPSE in LV dysfunction does not signify primary RV dysfunction

Prognostic Value

  • TAPSE <16 mm associated with HF readmission and mortality
  • Independent predictor of mortality in acute MI and HF
  • <11 mm indicative of severe RV dysfunction; consider mechanical support evaluation
  • Serial TAPSE decline (>2 mm/year) suggests disease progression
CLINICAL INSIGHT

Next Steps

Normal TAPSE (>16 mm)

  • Normal RV systolic function; standard monitoring
  • No RV-specific interventions required
  • Reassess if clinical deterioration or new symptoms

Mild–Moderate Dysfunction (11–16 mm)

  • Assess for cause: PH, HF, RV infarction, PE, primary RV disease
  • Serial echo monitoring every 6–12 months
  • Optimize HF therapy; consider diuretics if volume overloaded
  • Screen for PH with BNP/NT-proBNP and right heart catheter if indicated

Severe Dysfunction (<11 mm)

  • Urgent cardiology referral; assess for acute decompensation
  • Consider inotropic support if cardiogenic shock
  • Evaluate for MCS / transplant candidacy if advanced HF
  • Aggressive PH-directed therapy if pulmonary hypertension present

Complementary Calculators

CLINICAL INSIGHT

Evidence Base

Key Studies

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography.

Rudski LG, et al.J Am Soc Echocardiogr.2010
CLINICAL INSIGHT

Background

Development

TAPSE measurement has been used in echocardiography since the early 2000s, emerging from systolic RV functional assessment studies. Standardized by ASE and ESC guidelines; now considered part of fundamental RV assessment on every echocardiogram.

TAPSE

TAPSE: Tricuspid annular plane systolic excursion — simple M-mode measurement of RV systolic function.

mm

M-mode measurement of lateral tricuspid annulus displacement from diastole to systole

Normal Reference Values

>16 mm: Normal
14–16 mm: Mild Dysfunction
11–14 mm: Moderate Dysfunction
<11 mm: Severe Dysfunction
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • First-line RV systolic function assessment on echocardiography
  • Screening for RV dysfunction in pulmonary hypertension
  • Risk stratification post-MI (especially inferior/RV infarction)
  • Serial monitoring in HF, PH, and after lung transplant
  • Prognostic indicator in acute decompensated HF

Key Advantages

  • Simple M-mode measurement; reproducible and operator-independent
  • No contrast required; works in poor acoustic windows
  • Correlates with RV EF from cardiac MRI
  • ESC/ASE endorsed; part of routine echo protocols
CLINICAL INSIGHT

How it Works

Measurement Technique

  • Obtained in apical 4-chamber view (M-mode)
  • Cursor placed at lateral tricuspid annulus (not at RV free wall)
  • Measure systolic displacement from annular position in diastole to systole
  • Measured in mm; independent of image angle

Normal & Abnormal Values

TAPSE (mm)RV Systolic FunctionPrognosis
>16NormalNormal RV function
14–16Mild DysfunctionMildly reduced
11–14Moderate DysfunctionModerately reduced
<11Severe DysfunctionSevere reduction; high mortality risk
CLINICAL INSIGHT

Practical Pearls

Technical Notes

  • Must be lateral annulus (not at septum); septum shows reduced excursion by design
  • Reported as single value; not averaged across cardiac cycles
  • Angle-independent; true linear excursion measurement
  • Reduced TAPSE in LV dysfunction does not signify primary RV dysfunction

Prognostic Value

  • TAPSE <16 mm associated with HF readmission and mortality
  • Independent predictor of mortality in acute MI and HF
  • <11 mm indicative of severe RV dysfunction; consider mechanical support evaluation
  • Serial TAPSE decline (>2 mm/year) suggests disease progression
CLINICAL INSIGHT

Next Steps

Normal TAPSE (>16 mm)

  • Normal RV systolic function; standard monitoring
  • No RV-specific interventions required
  • Reassess if clinical deterioration or new symptoms

Mild–Moderate Dysfunction (11–16 mm)

  • Assess for cause: PH, HF, RV infarction, PE, primary RV disease
  • Serial echo monitoring every 6–12 months
  • Optimize HF therapy; consider diuretics if volume overloaded
  • Screen for PH with BNP/NT-proBNP and right heart catheter if indicated

Severe Dysfunction (<11 mm)

  • Urgent cardiology referral; assess for acute decompensation
  • Consider inotropic support if cardiogenic shock
  • Evaluate for MCS / transplant candidacy if advanced HF
  • Aggressive PH-directed therapy if pulmonary hypertension present

Complementary Calculators

CLINICAL INSIGHT

Evidence Base

Key Studies

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography.

Rudski LG, et al.J Am Soc Echocardiogr.2010
CLINICAL INSIGHT

Background

Development

TAPSE measurement has been used in echocardiography since the early 2000s, emerging from systolic RV functional assessment studies. Standardized by ASE and ESC guidelines; now considered part of fundamental RV assessment on every echocardiogram.